Regenerative Engineering and Translational Medicine is an esteemed academic journal published by Springer Heidelberg, focusing on the interdisciplinary fields of biomaterials, biomedical engineering, and cell biology. With an ISSN of 2364-4133 and an E-ISSN of 2364-4141, the journal has carved a niche for itself since its inception in 2015, showcasing cutting-edge research that bridges the gap between scientific findings and practical applications in regenerative medicine. As a recognized platform in its field, it is currently positioned within Q3 quartiles in biomaterials, biomedical engineering, and medicine (miscellaneous), with a Scopus ranking that reflects its growing influence among peers. The journal aims to disseminate high-quality, peer-reviewed articles that highlight advancements in regenerative engineering, further advancing both theoretical and applied research. Scholars and practitioners seeking to stay at the forefront of the ever-evolving landscape of regenerative health solutions will find invaluable insights and innovations within these pages. Join a community of leading thinkers and explore the journal's comprehensive research contributions, which are crucial for fostering partnerships between academia and industry in the quest for transformative medical solutions.

CELL PROLIFERATION, published by Wiley, is a leading open-access journal that has been at the forefront of research since its inception in 1968. With an impact factor that solidifies its position in the Q1 category of both Cell Biology and Medicine (Miscellaneous), this journal serves as a premier platform for disseminating groundbreaking studies in the field of cellular and molecular biology. The journal is renowned for its rigorous peer-review process and comprehensive coverage of topics related to cell growth, division, and differentiation, making it an invaluable resource for researchers, professionals, and students alike. With its notable Scopus ranking of #30 in Biochemistry, Genetics, and Molecular Biology: Cell Biology, and a robust open access model since 2019, CELL PROLIFERATION ensures that cutting-edge research is accessible to a global audience, fostering collaboration and innovation across the scientific community. Located in the United Kingdom, the journal remains committed to enhancing the understanding of cellular processes, thereby influencing developments in medicine and biotechnology.

BIOCELL is a distinguished peer-reviewed journal dedicated to the field of Cell Biology, published by TECH SCIENCE PRESS. Since its inception in 1995, the journal has been at the forefront of disseminating innovative research, with converged publication years extending from 1995 to 2013 and from 2015 to 2024. Although it currently holds a Q4 ranking in the Cell Biology category according to the 2023 category quartiles, BIOCELL aims to foster advancements by providing a platform for researchers, professionals, and students to share their findings in biochemistry, genetics, and molecular biology. The journal is available in both print (ISSN: 0327-9545) and digital formats (E-ISSN: 1667-5746) and seeks to attract contributions that enhance scholarly dialogue and understandings of cellular mechanisms and innovations. With a commitment to quality research and critical discourse, BIOCELL plays an important role in nurturing the scientific community within Argentina and beyond, offering vital insights that contribute to the advancement of the life sciences.

Cellular Reprogramming is a prominent academic journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of cellular biology and biotechnology. With its ISSN 2152-4971 and E-ISSN 2152-4998, this journal provides an innovative platform for researchers and professionals to share groundbreaking research findings on cellular reprogramming, stem cell biology, and regenerative medicine. Established in 2010, and actively publishing until 2024, the journal is recognized for its contributions, evidenced by its categorizations in the Q3 and Q4 quartiles across several related fields, including biotechnology and developmental biology. This peer-reviewed journal not only supports open access to scientific literature but also aims to enhance interdisciplinary collaboration among scientists. With a growing impact in the realms of biochemistry, genetics, and molecular biology, Cellular Reprogramming remains an essential resource for the dissemination of pioneering research that could shape the future of cellular therapies.

Journal of Tissue Engineering and Regenerative Medicine, published by WILEY, stands as a pivotal platform in the fields of biomaterials, biomedical engineering, and regenerative medicine. With an ISSN of 1932-6254 and an E-ISSN of 1932-7005, this journal, based in the United Kingdom, has consistently delivered high-quality research since its inception in 2006, converging critical insights through 2024. With an impressive citation profile reflected in its Scopus rankings—specifically a rank of #58 in Medicine and #75 in Biomedical Engineering—the journal is acknowledged for its substantial impact, as demonstrated by its competitive quartile standings in 2023. Notably, it maintains a Q3 ranking in Biomaterials and Q2 in both Biomedical Engineering and Medicine (miscellaneous), showcasing its influence and relevance in the rapidly evolving interplay between engineering and medicine. The journal serves as a vital resource for researchers and practitioners aiming to stay abreast of innovations and breakthroughs in regenerative therapies, tissue scaffolds, and biomaterials. While not an open-access publication, it fosters academic dialogue and knowledge dissemination that is crucial for advancing the field.

BLOOD CELLS MOLECULES AND DISEASES is a prominent multidisciplinary journal published by Academic Press Inc., Elsevier Science, specializing in the fields of hematology, molecular biology, and cell biology. With an ISSN of 1079-9796 and an E-ISSN of 1096-0961, this journal serves as a vital resource for researchers, professionals, and students exploring the complex interplay between blood cells and their corresponding molecular pathways in disease states. Spanning topics from cellular mechanisms to therapeutic advancements, BLOOD CELLS MOLECULES AND DISEASES holds a commendable reputation with a 2023 category quartile ranking of Q2 in Hematology and Q3 in several related fields. This journal not only provides a platform for the dissemination of innovative research but also fosters collaboration and knowledge exchange within the scientific community. As it converges from 1995 to 2025, the journal continues to impact the medical and biological sciences significantly, making it an essential tool for advancing our understanding of hematologic diseases.

Stem Cell Reports, published by CELL PRESS, is a distinguished open access journal that has been providing critical insights into the dynamic field of stem cell research since its launch in 2013. With a focus on advancing knowledge in Biochemistry, Cell Biology, Developmental Biology, and Genetics, the journal holds a prestigious Q1 ranking across these categories in 2023, underscoring its significant impact and leadership within the scientific community. The journal occupies a prominent position in the Scopus rankings, notably achieving a remarkable percentile ranking in multiple disciplines, which reflects its rigorous peer-review process and the high quality of the research it disseminates. Accessible to a global audience, Stem Cell Reports not only facilitates the open exchange of innovative findings but also serves as a pivotal resource for researchers, professionals, and students dedicated to exploring the potential of stem cells in regenerative medicine and biotechnology. The journal is committed to supporting the advancement of the field by showcasing groundbreaking research and fostering collaboration among scientists worldwide.

Stem Cell Research is a premier Open Access journal published by ELSEVIER, dedicated to advancing the understanding of stem cell biology. Since its inception in 2007, the journal has provided a platform for the latest research in the fields of Cell Biology, Developmental Biology, and Medicine, with its publication being accessible globally since 2014. Located in the Netherlands, the journal’s comprehensive scope aims to bridge fundamental discoveries with clinical applications, fostering collaboration among researchers and professionals. With a 2023 impact factor reflected in its Q4 ranking in Cell and Developmental Biology and a commendable position in the 64th percentile for General Medicine, Stem Cell Research remains a vital resource for those interested in the dynamic landscape of regenerative medicine. Targeting an audience that includes researchers, practitioners, and students, the journal emphasizes not only the significance of stem cells in medical science but also the ethical considerations and the public discourse surrounding stem cell research. Join the community committed to pioneering the future of stem cell science through rigorous peer-reviewed research.

Stem Cells Translational Medicine, published by Oxford University Press, is a leading open-access journal that has been at the forefront of stem cell research since its launch in 2012. With an impressive impact across various categories, it occupies Q2 in Cell Biology and is highly recognized in Q1 for both Developmental Biology and Miscellaneous Medicine in 2023. Its strong Scopus rankings highlight its significance in the fields of Biochemistry, Genetics, and Molecular Biology, achieving an outstanding percentile ranking of 93rd in Developmental Biology. The journal provides a pivotal platform for researchers, professionals, and students to publish and access cutting-edge findings that contribute to the understanding and application of stem cell technology. With a commitment to disseminating high-quality scientific knowledge, Stem Cells Translational Medicine plays a vital role in advancing research and innovation within the rapidly evolving landscape of regenerative medicine.

Cells, published by MDPI in Switzerland, is a leading open-access journal that has been disseminating groundbreaking research in the fields of Biochemistry, Genetics, and Molecular Biology since its inception in 2011. With an impressive E-ISSN of 2073-4409, the journal boasts a strong impact factor and ranks in the 84th percentile for Scopus ratings, underscoring its significance in advancing scientific knowledge. As a Q1-ranked journal in both 2023 and 2020, it serves as a premier platform for researchers, professionals, and students eager to explore innovative findings and methodologies. By providing unrestricted access to high-quality research, Cells plays a pivotal role in facilitating collaboration and inspiration within the global scientific community, making it an indispensable resource for anyone interested in cutting-edge discoveries in cellular biology.